Research & Development

Drug Development

Subscribe to Drug Development
View Sample

FREE Email Newsletter

R&D Daily

Clinical trial uncovers potential cure for HIV

October 6, 2011 10:33 am | News | Comments

Data from a clinical trial involving University of California, Los Angeles researchers suggest that a new therapy may potentially serve as a "functional cure" for HIV/AIDS. The therapy, called SB-728-T, involves the modification of both copies of a patient's CCR5 gene, which encodes the major co-receptor used by HIV to infect immune system cells.

Purdue part of institute awarded up to $35 million by FDA

October 6, 2011 6:38 am | News | Comments

Purdue University is part of a national institute that received a grant of up to $35 million over the next five years from the U.S. Food and Drug Administration (FDA). The FDA awarded the grant to the National Institute for Pharmaceutical Technology and Education, or NIPTE, to improve manufacturing standards and ultimately cut health care costs, create jobs, and improve drug safety.

Rutgers, UMDNJ research provides insight into fighting viruses

September 30, 2011 5:16 am | News | Comments

Researchers at Rutgers University and UMDNJ-Robert Wood Johnson Medical School have determined the structure of a protein that is the first line of defense in fighting viral infections including influenza, hepatitis C, West Nile, rabies, and measles.

Advertisement

SwRI receives contract to develop drug formulation to treat cyanide exposure

September 16, 2011 10:38 am | News | Comments

Southwest Research Institute was awarded a $4.4 million contract from the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority to develop a nasal-delivery, first-line treatment system to combat cyanide poisoning.

Scientists reengineer antibiotic to overcome resistent bacteria

August 25, 2011 7:32 am | News | Comments

A team of scientists from The Scripps Research Institute have successfully reengineered an important antibiotic to kill the deadliest antibiotic-resistant bacteria. The researchers report the finding has clinical significance.

Scientists create natural Alzheimer's-fighting compound in lab

August 25, 2011 4:20 am | News | Comments

Scientists at Yale University have developed the first practical method to create a compound called huperzine A in the laboratory. The compound, which occurs naturally in a species of moss found in China, is an enzyme inhibitor that has been used to treat Alzheimer's disease in China since the late 1990s and is sold in the U.S. as a dietary supplement to help maintain memory.

Cresset, Redx Pharma announce drug discovery collaboration

August 24, 2011 7:50 am | News | Comments

Cresset and Redx Pharma announced that they have signed a major drug discovery collaboration, which gives Redx Pharma access to Cresset's computational chemistry technologies for use on their portfolio of drug discovery programs.

Sweet discovery could speed drug development

August 22, 2011 5:06 am | News | Comments

In a new study, University of Wisconsin-Madison researchers have described a simple process to separate sugars from a carrier molecule, then attach them to a drug or other chemical.

Advertisement

New drug could cure nearly any viral infection

August 10, 2011 4:34 am | by Anne Trafton, MIT News Office | News | Comments

Most bacterial infections can be treated with antibiotics such as penicillin. However, such drugs are useless against viral infections. Now, in a development that could transform how viral infections are treated, a team of researchers at the Massachusetts Institute of Technology's Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.

Antibody recognizes many strains of flu virus

August 8, 2011 11:53 am | News | Comments

Unlike many vaccines, the shot for influenza needs yearly updating. Howard Hughes Medical Institute scientists have discovered a human antibody that recognizes many different flu strains and could be the basis for a longer-lasting vaccine.

Sperm from mice stem cells offers infertility hope

August 8, 2011 6:07 am | News | Comments

A team of scientists at Kyoto University has reported producing viable sperm using the stem cells of mice in an experiment that researchers hope could one day lead to treating infertile men.

Drug prices to plummet in wave of expiring patents

July 25, 2011 5:00 am | by Linda A. Johnson, AP Business Writer | News | Comments

The next 14 months will bring generic versions of seven of the world's 20 best-selling drugs, including the top two: cholesterol fighter Lipitor and blood thinner Plavix. Generic competition will decimate sales of the brand-name drugs and cut costs to patients and companies that provide health benefits.

Newly designed molecule blocks chlamydia bacteria

July 22, 2011 8:09 am | News | Comments

Researchers at Duke University Medical Center have discovered a way to block the damaging actions of chlamydia. The team, which included Duke University microbiologists and chemists, designed a molecule that takes away the bacteria's self-defense mechanisms.

Novel biodegradable pellet targets glue ear infection

July 21, 2011 6:16 am | News | Comments

Scientists at The University of Nottingham have developed a novel biodegradable pellet, which over a period of three weeks, will release effective quantities of antibiotics into the middle ear, targeting glue ear infection.

Neutralizing HIV

July 18, 2011 5:12 am | by Katie Neith | News | Comments

A study involving researchers at Caltech points to the possibility of using neutralizing antibodies in the development of a vaccine for HIV. Their research describes a group of novel antibodies that were isolated from HIV-infected individuals using a new cloning approach.

Scientists unlock cellular sodium channel

July 14, 2011 8:26 am | by Leila Gray | News | Comments

Researchers at the University of Washington have determined the atomic architecture of a sodium channel. The achievement opens new possibilities for better drugs to address pain, epilepsy, and heart rhythm disturbances.

Recreating human livers, in mice

July 12, 2011 4:27 am | by Anne Trafton, MIT News Office | News | Comments

Although scientists commonly use mice for biomedical research, they are not always helpful for pharmaceutical testing. Because mouse livers react to drugs differently than human livers, they often can't be used to predict whether a potential drug will be toxic to people. That means that a drug that harms the liver could make it all the way to human clinical trials before researchers discover its risks. Now, a graduate student in the MIT-Harvard Division of Health Sciences and Technology (HST), has developed a way to overcome that problem by growing human liver tissue inside mice.

Plastic cell membranes for faster and cheaper drug development

June 30, 2011 7:18 am | News | Comments

Synthetic cell membranes invented at the Institute of Materials Research and Engineering (IMRE), a research institute of Singapore's Agency for Science, Technology and Research (A*STAR), may improve the way we identify and develop drugs by speeding up and reducing the cost of the drug screening process.

Scientists crack histamine code in effort to reduce side effects

June 28, 2011 5:48 am | News | Comments

An international team of scientists using Diamond Light Source, the UK’s national synchrotron facility, has successfully solved the complex 3D structure of the human Histamine H1 receptor protein. The breakthrough, which involved Scripps Institute researchers, lets scientists begin work on third-generation anti-histamine drugs that reduce side effects.

Hitting moving RNA drug targets

June 27, 2011 4:43 am | News | Comments

By accounting for the floppy, fickle nature of RNA, researchers at the Univ. of Michigan and the Univ. of California, Irvine have developed a new way to search for drugs that target this important molecule.

Revealing HIV's weakness

June 21, 2011 4:00 am | by Anne Trafton, MIT News Office | News | Comments

Ever since HIV was revealed as the infectious agent behind the AIDS epidemic, scientists have been striving to develop a vaccine against the disease. However, the task has proven difficult, because HIV mutates so rapidly. In a new finding that may allow vaccine designers to sidestep part of that obstacle, researchers at the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard Univ. have identified sections of an HIV protein where mutations would actually undermine the virus’ ability to survive and reproduce.

An alternative to antibiotics?

June 7, 2011 12:45 pm | News | Comments

Antibiotics are among the greatest achievements of medical science. But bacteria are increasingly developing resistance to once-potent drugs. Researchers are scrambling for an alternative, and researchers in Germany say they have found one in a therapeutic equivalent that could replace penicillin and related pharmaceuticals.

Potential treatment for E. coli disease

June 7, 2011 7:04 am | News | Comments

A potential life-saving treatment for severe E. coli food poisoning outbreaks—developed more than a decade ago—hasn't gone forward into clinical trials because of lack of commercial interest. Univ. of Adelaide researchers produced a "designer" probiotic bacterium which binds and neutralizes the toxin produced by E. coli , which causes life-threatening attack on the kidneys and blood vessels.

Scientists find compounds for use in basic research and drug development

May 23, 2011 5:22 am | News | Comments

Scientists from The Scripps Research Institute have identified a class of compounds that could be a boon to basic research and drug discovery. In a new study, the researchers show the new compounds powerfully and selectively block the activity of a large and diverse group of enzymes known as "serine hydrolases."

Organic catalyst to enhance drug R & D

May 13, 2011 9:17 am | News | Comments

A new "organocatalyst" developed at Oregon State Univ. is now available for commercial use. Produced by an Albany, Ore., pharmaceutical company, it should make new drug development around the world less costly, more efficient, and more environmentally friendly.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading